scholarly journals Spread of Vaccine-Derived Poliovirus from a Paralytic Case in an Immunodeficient Child: an Insight into the Natural Evolution of Oral Polio Vaccine

2005 ◽  
Vol 79 (2) ◽  
pp. 1062-1070 ◽  
Author(s):  
E. A. Cherkasova ◽  
M. L. Yakovenko ◽  
G. V. Rezapkin ◽  
E. A. Korotkova ◽  
O. E. Ivanova ◽  
...  
Keyword(s):  
Oral Polio Vaccine ◽  
Extended Period ◽  
Polio Eradication ◽  
Human Organism ◽  
Synonymous Mutations ◽  
Polio Vaccine ◽  
Recombinant Type ◽  
Eradication Campaign ◽  
Insight Into

ABSTRACT Sabin strains used in the manufacture of oral polio vaccine (OPV) replicate in the human organism and can give rise to vaccine-derived polioviruses. The increased neurovirulence of vaccine derivatives has been known since the beginning of OPV use, but their ability to establish circulation in communities has been recognized only recently during the latest stages of the polio eradication campaign. This important observation called for studies of their emergence and evolution as well as extensive surveillance to determine the scope of this phenomenon. Here, we present the results of a study of vaccine-derived isolates from an immunocompromised poliomyelitis patient, the contacts, and the local sewage. All isolates were identified as closely related and slightly evolved vaccine derivatives with a recombinant type 2/type 1 genome. The strains also shared several amino acid substitutions including a mutation in the VP1 protein that was previously shown to be associated with the loss of attenuation. Another mutation in the VP3 protein resulted in altered immunological properties of the isolates, possibly facilitating virus spread in immunized populations. The patterns and rates of the accumulation of synonymous mutations in isolates collected from the patient over the extended period of excretion suggest either a substantially nonuniform rate of mutagenesis throughout the genome, or, more likely, the strains may have been intratypic recombinants between coevolving derivatives with different degrees of divergence from the vaccine parent. This study provides insight into the early stages of the establishment of circulation by runaway vaccine strains.

scholarly journals Wild and vaccine-derived poliovirus circulation, and implications for polio eradication

2016 ◽  
Vol 145 (3) ◽  
pp. 413-419 ◽  
Author(s):  
P. L. LOPALCO
Keyword(s):  
Wild Strain ◽  
Oral Polio Vaccine ◽  
Polio Eradication ◽  
Poliovirus Type ◽  
Polio Vaccine ◽  
Vaccine Schedule ◽  
Long Time ◽  
High Level ◽  
Type 3

SUMMARYPolio cases due to wild virus are reported by only three countries in the world. Poliovirus type 2 has been globally eradicated and the last detection of poliovirus type 3 dates to November 2012. Poliovirus type 1 remains the only circulating wild strain; between January and September 2016 it caused 26 cases (nine in Afghanistan, 14 in Pakistan, three in Nigeria). The use of oral polio vaccine (OPV) has been the key to success in the eradication effort. However, paradoxically, moving towards global polio eradication, the burden caused by vaccine-derived polioviruses (VDPVs) becomes increasingly important. In this paper circulation of both wild virus and VDPVs is reviewed and implications for the polio eradication endgame are discussed. Between April and May 2016 OPV2 cessation has been implemented globally, in a coordinated switch from trivalent OPV to bivalent OPV. In order to decrease the risk for cVDPV2 re-emergence inactivated polio vaccine (IPV) has been introduced in the routine vaccine schedule of all countries. The likelihood of re-emergence of cVDPVs should markedly decrease with time after OPV cessation, but silent circulation of polioviruses cannot be ruled out even a long time after cessation. For this reason, immunity levels against polioviruses should be kept as high as possible in the population by the use of IPV, and both clinical and environmental surveillance should be maintained at a high level.

Towards Polio Eradication in Nigeria: Identifying at Risk Population for Low Oral Polio Vaccine (OPV) Uptake

PEDIATRICS ◽  
2016 ◽  
Vol 137 (Supplement 3) ◽  
pp. 389A-389A
Author(s):  
Oluyemisi O. Falope ◽  
Korede K. Adegoke ◽  
Chukwudi O. Ejiofor ◽  
Nnadozie C. Emechebe ◽  
Taiwo O Talabi ◽  
...  
Keyword(s):  
At Risk ◽  
Oral Polio Vaccine ◽  
Polio Eradication ◽  
Risk Population ◽  
Polio Vaccine

scholarly journals Inferring Numbers of Wild Poliovirus Excretors Using Quantitative Environmental Surveillance

Vaccines ◽  
2021 ◽  
Vol 9 (8) ◽  
pp. 870
Author(s):  
Yuri Perepliotchikov ◽  
Tomer Ziv-Baran ◽  
Musa Hindiyeh ◽  
Yossi Manor ◽  
Danit Sofer ◽  
...  
Keyword(s):  
Oral Polio Vaccine ◽  
Turnaround Time ◽  
Quantitative Detection ◽  
Environmental Surveillance ◽  
Wild Poliovirus ◽  
Polio Vaccine ◽  
Kinetic Information ◽  
Using Data ◽  
Number Of Individuals

Response to and monitoring of viral outbreaks can be efficiently focused when rapid, quantitative, kinetic information provides the location and the number of infected individuals. Environmental surveillance traditionally provides information on location of populations with contagious, infected individuals since infectious poliovirus is excreted whether infections are asymptomatic or symptomatic. Here, we describe development of rapid (1 week turnaround time, TAT), quantitative RT-PCR of poliovirus RNA extracted directly from concentrated environmental surveillance samples to infer the number of infected individuals excreting poliovirus. The quantitation method was validated using data from vaccination with bivalent oral polio vaccine (bOPV). The method was then applied to infer the weekly number of excreters in a large, sustained, asymptomatic outbreak of wild type 1 poliovirus in Israel (2013) in a population where >90% of the individuals received three doses of inactivated polio vaccine (IPV). Evidence-based intervention strategies were based on the short TAT for direct quantitative detection. Furthermore, a TAT shorter than the duration of poliovirus excretion allowed resampling of infected individuals. Finally, the method documented absence of infections after successful intervention of the asymptomatic outbreak. The methodologies described here can be applied to outbreaks of other excreted viruses such as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), where there are (1) significant numbers of asymptomatic infections; (2) long incubation times during which infectious virus is excreted; and (3) limited resources, facilities, and manpower that restrict the number of individuals who can be tested and re-tested.

scholarly journals Excretion of Wild-Type and Vaccine-Derived Poliovirus in the Feces of Poliovirus Receptor-Transgenic Mice

2003 ◽  
Vol 77 (11) ◽  
pp. 6541-6545 ◽  
Author(s):  
Hein J. Boot ◽  
Daniella T. J. Kasteel ◽  
Anne-Marie Buisman ◽  
Tjeerd G. Kimman
Keyword(s):  
Transgenic Mice ◽  
Oral Polio Vaccine ◽  
Fecal Excretion ◽  
Wild Type ◽  
Genetic Determinants ◽  
Poliovirus Type ◽  
Oral Transmission ◽  
Polio Vaccine ◽  
Poliovirus Receptor

ABSTRACT The emergence of circulating vaccine-derived poliovirus (cVDPV) strains in suboptimally vaccinated populations is a serious threat to the global poliovirus eradication. The genetic determinants for the transmissibility phenotype of polioviruses, and in particularly of cVDPV strains, are currently unknown. Here we describe the fecal excretion of wild-type poliovirus, oral polio vaccine, and cVDPV (Hispaniola) strains after intraperitoneal injection in poliovirus receptor-transgenic mice. Both the pattern and the level of fecal excretion of the cVDPV strains resemble those of wild-type poliovirus type 1. In contrast, very little poliovirus was present in the feces after oral polio vaccine administration. This mouse model will be helpful in elucidating the genetic determinants for the high fecal-oral transmission phenotype of cVDPV strains.

scholarly journals Advax-CpG Adjuvant Provides Antigen Dose-Sparing and Enhanced Immunogenicity for Inactivated Poliomyelitis Virus Vaccines

Pathogens ◽  
2021 ◽  
Vol 10 (5) ◽  
pp. 500
Author(s):  
Yoshikazu Honda-Okubo ◽  
Jeremy Baldwin ◽  
Nikolai Petrovsky
Keyword(s):  
Neutralizing Antibodies ◽  
Serum Antibody ◽  
Oral Polio Vaccine ◽  
Antigen Dose ◽  
Polio Vaccine ◽  
Antibody Titers ◽  
Dose Sparing ◽  
Sparing Effect ◽  
Eradicate Polio

Global immunization campaigns have resulted in a major decline in the global incidence of polio cases, with wild-type poliovirus remaining endemic in only two countries. Live oral polio vaccine (OPV) played a role in the reduction in polio case numbers; however, the risk of OPV developing into circulating vaccine-derived poliovirus makes it unsuitable for eradication programs. Trivalent inactivated polio virus (TIPV) vaccines which contain formalin-inactivated antigens produced from virulent types 1, 2 and 3 reference polio strains grown in Vero monkey kidney cells have been advocated as a replacement for OPV; however, TIPVs have weak immunogenicity and multiple boosts are required before peak neutralizing titers are reached. This study examined whether the incorporation of the novel polysaccharide adjuvant, Advax-CpG, could boost the immunogenicity of two TIPV vaccines, (i) a commercially available polio vaccine (IPOL®, Sanofi Pasteur) and (ii) a new TIPV formulation developed by Statens Serum Institut (SSI). Mice were immunized intramuscularly based on recommended vaccine dosage schedules and serum antibody titers were followed for 12 months post-immunization. Advax-CpG significantly enhanced the long-term immunogenicity of both TIPV vaccines and had at least a 10-fold antigen dose-sparing effect. An exception was the poor ability of the SSI TIPV to induce serotype type 1 neutralizing antibodies. Immunization with monovalent IPVs suggested that the low type 1 response to TIPV may be due to antigen competition when the type 1 antigen was co-formulated with the type 2 and 3 antigens. This study provides valuable insights into the complexity of the formulation of multivalent polio vaccines and supports the further development of adjuvanted antigen-sparing TIPV vaccines in the fight to eradicate polio.

scholarly journals Impact of Maternal Antibody on the Immunogenicity of Inactivated Polio Vaccine in Infants Immunized With Bivalent Oral Polio Vaccine: Implications for the Polio Eradication Endgame

2018 ◽  
Vol 67 (suppl_1) ◽  
pp. S57-S65 ◽  
Author(s):  
James T Gaensbauer ◽  
Chris Gast ◽  
Ananda S Bandyopadhyay ◽  
Miguel O’Ryan ◽  
Xavier Saez-Llorens ◽  
...  
Keyword(s):  
Oral Polio Vaccine ◽  
Polio Eradication ◽  
Maternal Antibody ◽  
Inactivated Polio Vaccine ◽  
Polio Vaccine

scholarly journals Post-polio eradication: vaccination strategies and options for India

2014 ◽  
Vol 2 (2) ◽  
Author(s):  
Jayakrishnan Thayyil ◽  
Thejus Jayakrishnan
Keyword(s):  
International Health ◽  
Main Tool ◽  
Oral Polio Vaccine ◽  
Polio Eradication ◽  
World Health ◽  
Wild Poliovirus ◽  
Polio Vaccine ◽  
Vaccination Strategies ◽  
Health Agencies ◽  
Health Organization

In 1988, the World Health Organization (WHO) resolved to eradicate poliomyelitis globally. Since then, the initiative has reported dramatic progress in decreasing the incidence of poliomyelitis and limiting the geographical extent of transmission. 2013 is recorded as the second consecutive year not reporting wild poliovirus (WPV) from India. If the country can retain this position for one more year India will be declared as polio eradicated. What should be the future vaccination strategies? We searched and reviewed the full text of the available published literature on polio eradication via PubMed and examined Internet sources and websites of major international health agencies. The oral polio vaccine (OPV) has been the main tool in the polio eradication program. Once WPV transmission is interrupted, the poliomyelitis will be caused only by OPV. India could expect 1 vaccine-associated paralytic polio per 4.2-4.6 million doses of OPV. Considering the threat of vaccine-derived viruses to polio eradication, WHO urged to develop a strategy to safely discontinue OPV after certification. The ultimate aim is to stop OPV safely and effectively, and eventually substitute with inactivated polio vaccine (IPV). The argument against the use of IPV is its cost. From India, field based data were available on the efficacy of IPV, which was better than OPV. IPV given intradermally resulted in seroconversion rates similar to full-dose intramuscular vaccine. The incremental cost of adopting IPV to replace OPV is relatively low, about US $1 per child per year, and most countries should be able to afford this additional cost.

scholarly journals Assessing the stability of polio eradication after the withdrawal of oral polio vaccine

PLoS Biology ◽  
2018 ◽  
Vol 16 (4) ◽  
pp. e2002468 ◽  
Author(s):  
Michael Famulare ◽  
Christian Selinger ◽  
Kevin A. McCarthy ◽  
Philip A. Eckhoff ◽  
Guillaume Chabot-Couture
Keyword(s):  
Oral Polio Vaccine ◽  
Polio Eradication ◽  
Polio Vaccine ◽  
The Stability

scholarly journals Protecting investments in polio eradication: the past, present and future of surveillance for acute flaccid paralysis

2004 ◽  
Vol 132 (5) ◽  
pp. 779-780 ◽  
Author(s):  
D. L. HEYMANN ◽  
E. M. DE GOURVILLE ◽  
R. B. AYLWARD
Keyword(s):  
Acute Flaccid Paralysis ◽  
Oral Polio Vaccine ◽  
Policy Decision ◽  
Polio Eradication ◽  
Global Policy ◽  
Wild Poliovirus ◽  
The Road ◽  
Polio Vaccine ◽  
The Past ◽  
Consultation Group

In September 2003 a WHO consultation group on vaccine-derived polioviruses (VDPV) concluded that in order to prevent future generations of paralytic polio after interruption of transmission of wild poliovirus, the use of trivalent oral polio vaccine (OPV) must be stopped [1]. Another important global policy decision along the road to polio eradication thus became possible – cessation of OPV use at some time after eradication. The question now is not whether OPV must be stopped, but rather when.

scholarly journals The Pathology of Poliomyelitis and the Vaccines and Nonvaccine Therapy

2021 ◽  
Vol 308 ◽  
pp. 02018
Author(s):  
Yushuo Chen ◽  
Tianrui Yue ◽  
Zixiao Zhang
Keyword(s):  
Developing Countries ◽  
Nervous System ◽  
Low Cost ◽  
Oral Polio Vaccine ◽  
Polio Eradication ◽  
Paralytic Poliomyelitis ◽  
Strongly Correlated ◽  
Inactivated Polio Vaccine ◽  
Polio Vaccine ◽  
New Type

Poliomyelitis is an exclusively human disease that mainly affects children. Clinical features of poliomyelitis can be varied, from mild illness to the most severe paralysis, and the factor why poliomyelitis has different performances in individuals has been proved strongly correlated with membrane protein CD155. The nervous system shows a special protecting phenomenon against the invasion of poliovirus, and the mechanism is not very clear at present. Vaccines are the main means of preventing and controlling polio, and many different vaccines have been invented in the process of fighting polio. Inactivated polio vaccine (IPV) and oral polio vaccine (OPV) are the two main vaccines. IPV is known for its safety while OPV is widely used in developing countries because of its relatively low cost. This usage also leads to some side effects: vaccine-associated paralytic polio (VAPP) and vaccine-derived poliovirus (VDPV). Now, for polio eradication, the elimination of these two diseases has become particularly important. Thus, a new type of vaccine was created: sequential IPV-OPV with the safety of IPV and the low cost of OPV. This paper will talk about the different polio vaccines and their effects. An enormous difference between people who have gotten the vaccine and people who have not got the vaccine. Comparing the two kinds of people, people who get normal poliovirus, and people who get poliovirus after taking a vaccine, known as VAPP (vaccine-associated paralytic poliomyelitis), the former cannot get full recovery whole life and the latter has a very low possibility. In conclusion, people should take vaccines if it is affordable for them.

Sign in / Sign up

Export Citation Format

Share Document